Novo Nordisk (NVO) details DKK 7.78B in B-share repurchases under 2026 programme

Rhea-AI Filing Summary

Novo Nordisk A/S provides an update on its ongoing B-share repurchase activity. As part of an overall programme of up to DKK 15 billion over 12 months beginning 4 February 2026, the company is executing a sub-programme, initiated 6 May 2026, to repurchase B shares for up to DKK 11,200,000,010.45 through 1 February 2027.

Between 4 and 7 August 2026, Novo Nordisk repurchased a total of 820,000 B shares, bringing the accumulated amount under this sub-programme to 13,125,000 B shares for DKK 3,980,067,920. Separate incentive-related transactions led to a net transfer of 3,144,604 shares from Novo Nordisk during the same period, outside the Safe Harbour programme. After these transactions, Novo Nordisk holds 41,924,876 B shares as treasury shares, equal to 0.9% of its total share capital of 4,465,000,000 A and B shares. Since 4 February 2026, the company has repurchased 27,884,179 B shares at an average price of DKK 279.01, for a total of DKK 7,780,067,909.

Key Figures

Overall buyback capacity: DKK 15 billion Sub-programme limit: DKK 11,200,000,010.45 Accumulated sub-programme purchases: 13,125,000 B shares; DKK 3,980,067,920 +5 more

8 metrics

Overall buyback capacity DKK 15 billion Total B-share repurchase amount over 12 months from 4 February 2026

Sub-programme limit DKK 11,200,000,010.45 Maximum B-share repurchases under programme initiated 6 May 2026 to 1 February 2027

Accumulated sub-programme purchases 13,125,000 B shares; DKK 3,980,067,920 Total B shares and value repurchased under the 6 May 2026 sub-programme

Total 2026 repurchases 27,884,179 B shares; DKK 7,780,067,909 B shares and value repurchased since 4 February 2026 at average DKK 279.01

Treasury shares 41,924,876 B shares (0.9%) B shares of DKK 0.10 held as treasury shares as of 7 August 2026

Total share capital 4,465,000,000 A and B shares Total number of company shares including treasury shares

Employees 68,800 people Number of employees globally

Country footprint 80 countries; 170 markets Countries with employees and countries where products are marketed

Key Terms

share repurchase programme, Safe Harbour Rules, treasury shares, MAR

4 terms

share repurchase programme financial

"Novo Nordisk initiated a share repurchase programme in accordance with Article 5"

A share repurchase programme is a company's plan to buy back its own shares from the market. This reduces the total number of shares available, which can increase the value of remaining shares and signal confidence in the company's health. For investors, it can indicate that the company believes its stock is undervalued and may lead to higher share prices.

Safe Harbour Rules regulatory

"the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules")"

treasury shares financial

"Novo Nordisk owns a total of 41,924,876 B shares of DKK 0.10 as treasury shares"

Treasury shares are a company’s own stock that it has repurchased and keeps on its books instead of canceling or leaving in the hands of outside investors. Think of them like coupons a business puts back in a drawer: they don’t vote or receive dividends while held, but they can be reissued later for employee pay or fundraising. For investors this matters because buybacks change the number of shares that count toward earnings and ownership, can boost per‑share metrics, and use corporate cash that might otherwise go to growth or dividends.

MAR regulatory

"in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council ... (MAR)"

A market abuse regulation is a set of legal rules that forbid insider trading and deliberate manipulation of security prices and require fair disclosure of important company information. It works like a referee for markets, giving investors confidence that trades reflect real supply and demand rather than secret tips or engineered price moves, which helps protect the value of investments and the integrity of market prices.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

Available on EDGAR 08/10/2026 - 10:47 AM Accepted by SEC EDGAR 08/10/2026 - 10:47 AM Learn about SEC filing dates

FAQ

What share repurchase programme is Novo Nordisk (NVO) currently executing?

Novo Nordisk is executing an overall B-share repurchase programme of up to DKK 15 billion over 12 months beginning 4 February 2026, conducted under EU Safe Harbour Rules to support orderly buybacks.

How much has Novo Nordisk (NVO) repurchased so far in 2026?

As of 7 August 2026, Novo Nordisk has repurchased 27,884,179 B shares since 4 February 2026 at an average price of DKK 279.01, for a total transaction value of DKK 7,780,067,909.

What are the details of Novo Nordisk’s (NVO) May 2026 sub-programme?

The sub-programme launched on 6 May 2026 authorises repurchase of B shares for up to DKK 11,200,000,010.45 through 1 February 2027. Accumulated purchases under this sub-programme total 13,125,000 B shares for DKK 3,980,067,920.

How many treasury shares does Novo Nordisk (NVO) currently hold?

Novo Nordisk now holds 41,924,876 B shares of DKK 0.10 as treasury shares, representing 0.9% of its total 4,465,000,000 A and B shares outstanding, including treasury shares.

What share transactions were made by Novo Nordisk (NVO) between 4 and 7 August 2026?

From 4–7 August 2026, Novo Nordisk repurchased 820,000 B shares in the market and separately had incentive programme transactions resulting in a net transfer of 3,144,604 shares from the company, outside the Safe Harbour buyback.

What is the size of Novo Nordisk’s (NVO) global operations mentioned in this report?

Novo Nordisk employs about 68,800 people in 80 countries and markets its products in around 170 countries, reflecting the scale of its global healthcare operations.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

August 10, 2026

NOVO NORDISK A/S

 (Exact name of Registrant as specified in its charter)

Novo Allé 1

DK- 2880, Bagsvaerd

Denmark

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F ☒           Form 40-F ☐

 

 

Novo Nordisk A/S – Share repurchase programme

Bagsværd, Denmark, 10 August 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 4 February 2026.

Under the programme initiated 6 May 2026, Novo Nordisk will repurchase B shares for an amount up to DKK 11,200,000,010.45 in the period from 6 May 2026 to 1 February 2027.

Since the announcement 4 August 2026, the following transactions have been made:

	Number of B shares	Average purchase price	Transaction value, DKK
Accumulated, last announcement	12,305,000		3,733,256,468
4 August 2026	200,000	308.29	61,657,106
5 August 2026	215,000	294.26	63,266,938
6 August 2026	205,000	296.54	60,790,017
7 August 2026	200,000	305.49	61,097,391
Accumulated under the programme	13,125,000		3,980,067,920

The details for each transaction made under the share repurchase programme are published on novonordisk.com.

Transactions related to Novo Nordisk’s incentive programmes have resulted in a net transfer from Novo Nordisk of 3,144,604 shared in the period from 4 August 2026 to 7 August 2026. The shares in these transactions were not part of the Safe Harbour repurchase programme.

Page 2 of 2

With the transactions stated above, Novo Nordisk owns a total of 41,924,876 B shares of DKK 0.10 as treasury shares, corresponding to 0.9% of the share capital. The total amount of A and B shares in the company is 4,465,000,000 including treasury shares.

Novo Nordisk expects to repurchase B shares for an amount up to DKK 15 billion during a 12- month period beginning 4 February 2026. As of 7 August 2026, Novo Nordisk has since 4 February 2026 repurchased a total 27,884,179 B shares at an average share price of DKK 279.01 per B share equal to a transaction value of DKK 7,780,067,909.

Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 68,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.

Contacts for further information

Media:
Ambre James-Brown +45 3079 9289 globalmedia@novonordisk.com	Liz Skrbkova (US) +1 609 917 0632 USMediaRelations@novonordisk.com
Investors:
Michael Novod +45 3075 6050 nvno@novonordisk.com	Sina Meyer +45 3079 6656 azey@novonordisk.com
Alex Bruce +45 3444 2613 axeu@novonordisk.com	Ida Schaap Melvold +45 3077 5649 idmg@novonordisk.com
Christoffer Togo Solgaard-Tullin +45 3079 1471 cftu@novonordisk.com	Mads Berner Bruun +45 3075 2936 mbbz@novonordisk.com
Frederik Taylor Pitter (US) +1 609 613 0568 fptr@novonordisk.com

Novo Nordisk A/S Investor Relations	Novo Allé 1 2880 Bagsværd Denmark	Telephone: +45 4444 8888	www.novonordisk.com CVR no: 24 25 67 90
			Company announcement No 50 / 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

Date: August 10, 2026   NOVO NORDISK A/S   Maziar Mike Doustdar Chief Executive Officer